cemiplimab

Cemiplimab is a fully human monoclonal antibody and immune checkpoint inhibitor that targets programmed cell death protein 1 (PD-1) on T cells. By binding to PD-1 with high affinity, it blocks the interaction between PD-1 and its ligands (PD-L1 and PD-L2), which are often exploited by tumor cells to evade immune surveillance. This blockade restores T cell activity against tumors, promoting an immune-mediated antitumor response. Cemiplimab is primarily indicated for the treatment of advanced cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC) after hedgehog pathway inhibitor therapy or when such therapy is not appropriate, and as first-line or combination therapy for certain types of non-small cell lung cancer (NSCLC). It is developed by Regeneron Pharmaceuticals[1][3][4][5][6][8].

Brand names

Libtayo

Other names

cemiplimab-rwlc